PATHWORK TISSUE OF ORIGIN TEST KIT-FFPE (ORIGIN TEST KIT-FFPE

by PATHWORK DIAGNOSTICS  · Based in United States → — Precision Molecular Diagnostics for Oncology
Oncology Pathology

Contact for pricing
Regulatory Status Disclosed

Overview

The PATHWORK TISSUE OF ORIGIN TEST KIT-FFPE is a molecular diagnostic test designed to assist physicians in determining the primary site of origin for challenging cancer cases. It utilizes microarray-based RNA profiling to analyze gene expression patterns in formalin-fixed, paraffin-embedded (FFPE) tumor specimens. The test compares the patient’s tumor profile to a proprietary database of fifteen known tumor types, employing a machine learning-developed algorithm to generate Similarity Scores. This information aids in the diagnosis of poorly differentiated, undifferentiated, and metastatic tumors when the tissue of origin is uncertain after initial diagnostic workup. The kit includes the Pathchip® microarray, reagents, software, a Specimen Processing Guide, and a Guide to Report Interpretation.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Microarray-based RNA profiling for gene expression analysis
  • Compares tumor gene expression patterns to a database of 15 known tumor types
  • Utilizes proprietary analytics and Pathchipu00ae microarray
  • Generates 15 Similarity Scores indicating likelihood for each potential tissue of origin
  • Designed for formalin-fixed, paraffin-embedded (FFPE) tissue specimens
  • Aids in diagnosis of poorly differentiated, undifferentiated, and metastatic tumors
  • FDA-cleared as an in vitro diagnostic (IVD) kit
  • Includes reagents, software, and guides for specimen processing and report interpretation
  • Algorithm developed using machine learning methods and a large specimen database
  • Produces a comprehensive clinical report for physician interpretation

Use Cases

  • Determining the primary site of origin for metastatic or poorly differentiated tumors
  • Guiding evidence-based treatment decisions for cancer patients
  • Identifying the origin of carcinoma of unknown primary (CUP)
  • Complementing conventional pathology and immunohistochemistry when diagnosis is uncertain
  • Enabling enrollment in appropriate clinical trials based on tumor origin

What Physicians Need to Know

Key Capabilities
The Pathwork Tissue of Origin Test Kit-FFPE uses microarray technology to analyze gene expression patterns from formalin-fixed, paraffin-embedded (FFPE) tissue specimens. It measures the expression of over 1,500 genes in a tumor of uncertain origin and compares it to a database of 15 known tumor types, representing 90% of all solid tumors and 58 morphologies. The test helps identify the primary site of a tumor, particularly for metastatic, poorly differentiated, and undifferentiated tumors where the origin is unclear. The kit includes the Pathchip microarray, reagents, and software for specimen processing and report interpretation.
Clinical Utility
This test provides objective, actionable information to help physicians make more confident treatment decisions for patients with tumors of uncertain origin. By identifying the primary site, it enables the initiation of standard-of-care, tumor-specific therapy according to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines, potentially allowing patients to avoid ineffective chemotherapy. It is particularly useful when traditional diagnostic methods are insufficient.
Integration Options
The kit is designed for use in clinical laboratories, allowing pathologists to run the test in their own facilities. It utilizes the Pathchip microarray, which runs on the Affymetrix GeneChip System 3000Dx. The software component includes transmission software for uploading data to Pathwork for analysis and receiving a clinical report.
Compliance Status
The Pathwork Tissue of Origin Test Kit-FFPE is FDA-cleared as an in vitro diagnostic (IVD) kit. It was cleared by the FDA in 2010 for use with FFPE tissues. The test is classified as a Class II device under 21 CFR § 862.3100, with product code OIW for software and similarity score algorithm for tissue of origin for malignant tumor types.
Evidence Base
In a clinical validation study using FFPE tumor specimens, the test demonstrated 89% positive percent agreement (sensitivity) with available diagnoses and greater than 99% negative percent agreement (specificity). This study involved 352 metastatic, poorly differentiated, and undifferentiated tumors. The test measures the degree of similarity between the RNA expression patterns in a patient's FFPE tumor and a database of 15 tumor types. The test has been the subject of clinical studies to assess its impact on cancer-specific clinical decisions and outcomes.
Physician Tip

The Pathwork Tissue of Origin Test Kit-FFPE is particularly valuable for cases of metastatic, poorly differentiated, or undifferentiated tumors where the primary site is not readily identifiable through conventional methods. The results should be interpreted by a qualified physician in conjunction with the patient's clinical history and other diagnostic findings, such as immunohistochemistry. The test requires a minimum of 60% viable tumor in the FFPE specimen for optimal performance. While the test can handle up to 40% necrotic tissue, care should be taken to limit specimen exposure to RNases during handling.

The Pathwork Tissue of Origin Test Kit-FFPE is designed to be integrated into existing clinical laboratory workflows. It utilizes the Affymetrix GeneChip System 3000Dx for microarray analysis. The included transmission software facilitates data upload to Pathwork for analysis and subsequent receipt of a comprehensive clinical report.

Details

Category Oncology AI, Pathology AI
Pricing Contact for pricing
DeploymentLab-based test kit (for use in clinical laboratories); also offered as a service through CLIA-certified laboratories.
Compliance
BAA AvailableUnknown
HIPAA CompliantUnknown
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties Oncology, Pathology

FDA clearance history

This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.

Decision dateNumberName as listed by FDA
2010-06-08K092967 510(k)PATHWORK TISSUE OF ORIGIN TEST KIT-FFPE (ORIGIN TEST KIT-FFPE

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate PATHWORK TISSUE OF ORIGIN TEST KIT-FFPE (ORIGIN TEST KIT-FFPE

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for PATHWORK TISSUE OF ORIGIN TEST KIT-FFPE (ORIGIN TEST KIT-FFPE.

Loading videos...

View all on YouTube

Frequently Asked Questions

The PATHWORK TISSUE OF ORIGIN TEST KIT-FFPE is an in vitro diagnostic test designed to measure the similarity between the RNA expression patterns in a patient's formalin-fixed, paraffin-embedded (FFPE) tumor and a database of 15 known tumor types. This test aids physicians in diagnosing poorly differentiated, undifferentiated, and metastatic tumors when the primary site is uncertain, and should be interpreted alongside the patient's clinical history and other diagnostic results.
The test uses microarray-based RNA profiling to measure the expression levels of over 2,000 genes in a patient's tumor. This gene expression pattern is then compared to a database of 15 known tumor types using a similarity score algorithm to help determine the tumor's origin. The software component of the kit includes transmission software for uploading data and analytical software for generating the diagnostic report.
The PATHWORK TISSUE OF ORIGIN TEST KIT-FFPE is FDA-cleared as an in vitro diagnostic (IVD) device. It received FDA clearance in 2010 for use with FFPE tissues. This clearance allows it to be used broadly in clinical settings.
The test is not intended to establish the origin of tumors that cannot be diagnosed by current clinical and pathological practice, nor to subclassify or modify the classification of already diagnosable tumors. It also does not predict disease course, survival, or treatment efficacy, nor does it distinguish between primary and metastatic tumors. Additionally, tumor types not included in the test's database may have similar RNA expression patterns, meaning results cannot distinguish database tumor types from those not in the database.
While the Pathwork Tissue of Origin Test was noted as the only FDA-cleared molecular classification test for tissue of origin at the time of its clearance, other methods like immunohistochemistry are commonly used. Other molecular tests for FFPE tissues exist for various oncology applications, such as next-generation sequencing assays for hematologic malignancies or specific gene mutation detection kits.
In a clinical validation study using FFPE tumor specimens, the test demonstrated an 89% positive percent agreement (sensitivity) with available diagnoses and greater than 99% negative percent agreement (specificity). The test compares the patient's tumor RNA expression to a database of 15 tumor types, and a tissue with a similarity score of ≤5 can be ruled out with over 99% likelihood.

Related Tools

VERITON CT 400 Series Digital SPECT/CT System (VERITON CT 416/464)
Spectrum Dynamics Medical
Oncology AI
The VERITON CT 400 Series is a digital SPECT/CT system with a 360-degree gantry and 12 swiveling CZT detectors, offering high sensitivity and quantitative accuracy for a wide range of nuclear medicine applications, including advanced theranostics imaging.
syngo.via MI Workflows, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, syngo MBF is an intelligent, integrated imaging software that helps address the challenges of interpreting, managing, and sharing complex data from molecular imaging scanners, providing automated workflows and advanced visualization for various clinical applications.
syngo.via MI WorkFlows, Scenium, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, Scenium, and syngo MBF are medical diagnostic post-processing applications for viewing, manipulation, quantification, analysis, and comparison of PET or nuclear-medicine functional data with CT or MR anatomical data across timepoints, supporting disease management and radiotherapy treatment planning by trained healthcare professionals.
BIOGRAPH One
Siemens Healthineers AG
Oncology AI
BIOGRAPH One is a second-generation PET/MR scanner designed to transform PET/MR image quality for a new era, combining high PET precision with powerful MR performance. It enables simultaneous visualization of organ location, function, and cellular metabolism, offering faster image acquisition times and more efficient workflows than previous generations of PET/MR scanners.
Claire™ OCT System
Perimeter Medical Imaging AI
Oncology AI
Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultra-high resolution, real-time, advanced imaging tools that address unmet medical needs.S. for intraoperative breast cancer margin assessment.
syngo.via RT Image Suite VC10
Varian Medical Systems, Inc.
Clinical Decision Support & Reference
syngo.via RT Image Suite VC10 offers advanced imaging and workflow solutions for precise and efficient radiation therapy planning.

See all Oncology AI tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-11-11 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.